The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP)

Journal of the National Cancer Institute

Volumn 107, Issue 12, 2015, Pages djv261-

  Sweeney, Christopher ^a   Nakabayashi, Mari ^a   Regan, Meredith ^a   Xie, Wanling ^a   Hayes, Julia ^a   Keating, Nancy ^a   Li, Suhui ^a   Philipson, Tomas ^a   Buyse, Marc ^a   Halabi, Susan ^a   Kantoff, Philip ^a   Sartor, A Oliver ^a   Soule, Howard ^a   Mahal, Brandon ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BIOASSAY; BLOOD; COST BENEFIT ANALYSIS; DISEASE COURSE; DISEASE FREE SURVIVAL; ECONOMICS; HUMAN; LONGEVITY; MALE; META ANALYSIS; MULTICENTER STUDY (TOPIC); PROCEDURES; PROSTATECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS; STATISTICS; TIME; TREATMENT FAILURE; TRENDS; TUMOR RECURRENCE; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; LONGEVITY; MALE; MULTICENTER STUDIES AS TOPIC; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STATISTICS AS TOPIC; TIME FACTORS; TREATMENT FAILURE; UNITED STATES;

EID: 84999233469     PISSN: None     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv261     Document Type: Article

References (0)